Genetic associations with amyloid, tau, and neurodegeneration: an ADSP neuroimaging study

Elizabeth Mamourian, Jingxuan Bao, Yuhan Cui, Heng Huang, Andrew J. Saykin, Paul M. Thompson, Jason H. Moore, Marylyn D. Ritchie, Dokyoon Kim, Christos Davatzikos, Li ShenAlzheimer 2024 · DOI

TL;DR

This study leverages whole-genome sequencing and neuroimaging data to identify genetic variants associated with amyloid, tau, and neurodegeneration in Alzheimer's Disease (AD). They found significant genetic associations for all three AD pathologies, highlighting the role of APOE and chromosome 19 in amyloid and neurodegeneration, and a distinct genetic region on chromosome 6 linked to tau pathology.

What Problem Does This Paper Address?

Alzheimer's Disease (AD) is a complex neurodegenerative disorder characterized by the accumulation of amyloid plaques, tau tangles, and neuronal loss. The "amyloid-tau-neurodegeneration" (ATN) framework is a useful model for understanding AD, but the intricate interplay between these pathologies and their genetic underpinnings is not fully understood. This paper aims to bridge this gap by investigating how genetic variations influence these three key AD hallmarks using quantitative measures derived from neuroimaging.

Methods

The researchers utilized data from the Alzheimer's Disease Sequencing Project (ADSP), which includes harmonized whole-genome sequencing (WGS) and quantitative phenotype data. They performed Genome-Wide Association Studies (GWAS) using Plink on over 7.1 million genetic variants. The study analyzed three types of neuroimaging-derived quantitative traits:

  • Amyloid-PET features: Measuring amyloid accumulation.
  • Tau-PET features: Measuring tau pathology.
  • T1 MRI derived volumetric measures: Quantifying neurodegeneration in various brain regions.

GWAS analyses were conducted for each trait, controlling for principal components, age, and sex. For volumetric measures, intracranial volume was also included as a covariate.

Datasets

The study used data from the Alzheimer's Disease Sequencing Project (ADSP). This dataset includes:

  • Whole Genome Sequencing (WGS) data.
  • Quantitative neuroimaging phenotypes:
  • 3 Amyloid-PET features from N=1,217 participants.
  • 6 Tau-PET features from N=470 participants.
  • 20 T1 MRI derived volumetric measures of neurodegeneration from N=2,644 participants.

Key Insights and Ideas

  • Converging Genetic Signals: The study found that genetic variants associated with amyloid accumulation (amyloid positivity, centiloid values) also show associations with neurodegeneration (hippocampal volume). This suggests a shared genetic basis for these two AD hallmarks.
  • The Central Role of APOE and Chromosome 19: The strongest genetic associations for amyloid and neurodegeneration were found on chromosome 19, with lead single nucleotide polymorphisms (SNPs) located within or near the APOE gene. This reinforces APOE's well-established role in AD pathogenesis.
  • A Distinct Tau Pathway: Interestingly, a specific genetic region on chromosome 6 was significantly associated with tau pathology (Braak staging) but not with amyloid or neurodegeneration. This hints at a potentially independent genetic influence on tau accumulation.
  • ATN Framework Supported by Genetics: The findings provide robust genetic evidence supporting the ATN framework, demonstrating that genetic factors contribute to each of these core AD pathologies.

Key Results

The study identified genome-wide significant associations for all three ATN characteristics:

  • Amyloid phenotypes: N = 56 SNPs.
  • Tau phenotypes: N = 53 SNPs.
  • Neurodegeneration phenotypes: N = 77 SNPs.

The strongest associations for amyloid and neurodegeneration were localized to chromosome 19, near the APOE gene. A separate significant association for tau phenotypes was found on chromosome 6.

Limitations and Future Work

The authors acknowledge that the relationships between genetic factors and the ATN pathologies are complex. While this study identifies significant associations, further research is needed to elucidate the precise biological mechanisms by which these genetic variants influence amyloid, tau, and neurodegeneration. Future work could involve functional studies to understand the impact of these identified SNPs and explore interactions between genetic risk factors and environmental influences on AD progression.

Summary updated

Abstract

Abstract Background The amyloid‐tau‐neurodegeneration (ATN) framework provides a valuable model for comprehending the pathophysiology and progression of Alzheimer’s disease (AD). However the relationship between and genetic interaction with these three characteristics are complex and not fully understood. Here, we use neuroimaging‐derived quantitative traits to evaluate the genetic risk for amyloid accumulation, tau pathology, and neurodegeneration. Method The Alzheimer’s Disease Sequencing Project (ADSP) collected and harmonized whole genome sequencing (WGS) and quantitative phenotype data. This study examines harmonized neuroimaging traits, including 3 Amyloid‐PET features in N = 1,217 participants (Age = 72.6±8.1 years, Sex = 48.9% female), 6 Tau‐PET features in N = 470 participants (Age = 74.0±8.6 years, Sex = 53.8% female), and 20 selected T1 MRI derived volumetric measures of neurodegeneration in N = 2,644 participants (Age = 72.6±8.3 years, Sex = 52.0% female). We conducted genome wide association studies (GWAS) using Plink on the QC'ed WGS data of over 7.1 million variants for each trait, correcting for the top 10 principal components, age, and sex; for volumetric measures, we also control for intracranial volume. Result We found associations at the genome‐wide significance threshold for all three characteristics, including N = 56 SNPs associated with Amyloid phenotypes, N = 53 SNPs associated with Tau phenotypes, and N = 77 SNPs associated with Neurodegeneration phenotypes (Fig. 1). The strongest associations to Amyloid phenotypes (amyloid positivity, centiloid values) overlap with Neurodegeneration phenotypes (hippocampal volume) in chromosome 19, with the lead SNPs located in APOE . We found an additional region on chromosome 6 significantly associated with Tau phenotypes (Braak staging), but not Amyloid or Neurodegenerative phenotypes (Fig. 2). Conclusion These results provide additional evidence supporting the genetic contributions to risk of ATN pathology, confirming that variants in APOE and the surrounding region of chromosome 19 are strongly associated to amyloid positivity and hippocampal atrophy. These findings also support the genetic basis of a tau‐specific AD pathway. These results yield new insights into the genetic risk for amyloid accumulation, tau pathology, and neurodegeneration using the harmonized ADSP quantitative traits.
BibTeX
@inproceedings{mamourian2024genetic,
  author = {Elizabeth Mamourian and Jingxuan Bao and Yuhan Cui and Heng Huang and Andrew J. Saykin and Paul M. Thompson and Jason H. Moore and Marylyn D. Ritchie and Dokyoon Kim and Christos Davatzikos and Li Shen},
  title = {{Genetic associations with amyloid, tau, and neurodegeneration: an ADSP neuroimaging study}},
  booktitle = {Alzheimer},
  year = {2024},
  doi = {10.1002/alz.094870},
}
Figure